Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | PYGB | P11216 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309481 | 1.00 | CA1 (0.47) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL4345382 | 1.00 | CA1 (0.47) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL8653916 | 0.90 | ALDH1A1 (0.48) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL1115743 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL308568 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL309095 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL308565 | 0.87 | ALDH1A1 (0.50) | CA1CA2CA9ALDH1A1THRB | |
| SCHEMBL31206852 | 0.84 | CA12 (0.45) | CA1CA2CA9PYGBGAA | |
| SCHEMBL22346509 | 0.83 | CA12 (0.48) | CA1CA2CA9PYGBGAA | |
| SCHEMBL23066316 | 0.81 | PYGB (0.41) | CA1CA2CA9PYGBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4314816-A2 | DIAGNOSTIC PROCESS FOR THE DETERMINATION OF PERIMENOPAUSE OR MENOPAUSE STATUS VIA ANALYSIS OF THE IGG GLYCOME | Genos d.o.o. (HR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022207537-A2 | DIAGNOSTIC PROCESS FOR THE DETERMINATION OF PERIMENOPAUSE OR MENOPAUSE STATUS VIA ANALYSIS OF THE IgG GLYCOME | GENOS D.O.O. (HR) | 2022-10-06 | — | — | WO | disclosed |
| EP-2347003-B1 | GALACTOSE ALPHA (1-3) GALACTOSE COMPOSITIONS | JANSSEN BIOTECH INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-2347003-A1 | GALACTOSE ALPHA (1-3) GALACTOSE COMPOSITIONS | Centocor Ortho Biotech Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100240871-A1 | Galactose Alpha(1-3) Galactose Compositions | RAJU T SHANTHA | 2010-09-23 | — | — | US | disclosed |
| WO-2010051227-A1 | GALACTOSE ALPHA (1-3) GALACTOSE COMPOSITIONS | CENTOCOR ORTHO BIOTECH INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240871-A1 | Galactose Alpha(1-3) Galactose Compositions | B3GAT3, ST3GAL3, B4GALT1 | CA1 384/4885CA2 1639/4885CA9 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.